Biosimilars Shake Off Doubters, Go on a Roll.
Seven biosimilars have crossed the FDA-approval finish line. The FDA has largely held to the abbreviated pathway it laid out originally. The big change is that the rest of the world is starting to understand it. Approvals are based upon "the totality of evidence," "analytic similarity," and clinical performance with much less emphasis placed on phase 3 trials.